Improvement in health‐related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half‐life recombinant <scp>FIX</scp> product

Abstract excerpt

INTRODUCTION: Health-related quality of life (HRQoL) of individuals with haemophilia has greatly improved with the use of factor replacement and routine prophylaxis. AIM: To explore the HRQoL of individuals with haemophilia B treated with nonacog beta pegol, an extended half-life recombinant factor IX, in a single-blind, randomized multinational phase III pivotal trial (paradigm(™) 2) and its open-label extension...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Hemophilia Treatment and Research
• Share to Orthopaedic implants and arthroplasty